Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664-1676.

Vlismas PP, Heymann JJ, Marboe CC, Jorde UP, Sims DB. Quadravalvular Noninfectious Endocarditis. JACC Case Rep. 2019;1(3):350-354.

Kyriakides K, Selkin G, Selkin B, Iwenofu H, Magro CM. Chronic Fibrosing Vasculitis in the Setting of Still Disease. J Clin Rheumatol. 2019;25(7):e127-e130.

Lee Y-, Uchida H, Smith H, Ito A, Sanchez T. The isolation and molecular characterization of cerebral microvessels. Nat Protoc. 2019;14(11):3059-3081.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, et al. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2047-2054.

Schwartz Z, Magro C, Nuovo G. The molecular-based differentiation of Heck's disease from its mimics including oral condyloma and white sponge nevus. Ann Diagn Pathol. 2019;43:151402.

McIntire PJ, Snow JT, Elsoukkary SS, Soong L, Sweeney J, Robinson BD, et al. Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value below 0.7 for positive for high-grade urothelial carcinoma and suspicious for high-grade urothelial carcinoma in urine cytology specimens. Cancer Cytopathol. 2019;127(2):120-124.

Droesch C, Magro C. A comedonal variant of chronic cutaneous lupus erythematosus: Case report and literature review. JAAD Case Rep. 2019;5(9):801-805.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.